Blog

Nelson Advisors served as co-advisors to Zetta Genomics on their sale to TriNetX.TriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsSource: <a href="https://trinetx.com/press-releases/trinetx-enhances-its-ability-to-federate-genomics-data-across-its-global-network-of-providers-through-the-acquisition-of-key-assets-of-zetta-genomics/" data-mce-href="https://trinetx.com/press-releases/trinetx-enhances-its-ability-to-federate-genomics-data-across-its-global-network-of-providers-through-the-acquisition-of-key-assets-of-zetta-genomics/">https://trinetx.com/press-releases/trinetx-enhances-its-ability-to-federate-genomics-data-across-its-global-network-of-providers-through-the-acquisition-of-key-assets-of-zetta-genomics/</a>Cambridge, MA and Cambridge, UK, April&nbsp; 2026. TriNetX, the world’s leading federated health data network, today announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX’s genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers’ ability to integrate phenotypic and multiomic data for improved care delivery and clinical research and enhances the ability of TriNetX’s life science customers to perform large-data research in a cost-effective manner. &nbsp;&nbsp;Zetta’s flagship platform, XetaBase, is a multiomic capture and analytics platform designed for population‑scale genomic analysis. XetaBase is currently in use by leading healthcare provider organizations, life sciences companies, and research institutes. &nbsp;TriNetX and Zetta have worked closely together since 2024 as part of TriNetX’s genomics data program. During this collaboration, the companies completed substantial technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data to deliver high-integrity, analytically robust insights. This work establishes a strong foundation for further expansion.&nbsp;“Through our partnership activities, led by our Chief Operating Officer Steve Kundrot and team, we have developed deep familiarity with Zetta’s leadership, technological prowess, and fit-for-purpose approach and have been consistently impressed with Zetta’s trusted healthcare provider relationships and robust analytics platform,” said Jeff Margolis, Executive Chairman of TriNetX. “Welcoming Zetta’s XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization.”&nbsp;Mr. Margolis continued, “This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures.” &nbsp;Jeffrey Brown, PhD, TriNetX Chief Scientific Officer added, “Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology, as we strongly believe the integration of different data types is essential to clinical and scientific progress.” &nbsp;&nbsp;“I am proud of what the Zetta team has built and excited to see XetaBase become part of the TriNetX array of data, software, and intelligence capabilities,” said Ignacio Medina Castello, Chief Executive Officer and Chief Technology Officer of Zetta Genomics. “From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale. Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners.”

Nelson Advisors served as co-advisors to Zetta Genomics on their sale to TriNetX

Nelson Advisors blog Healthcare.Digital has been referenced as a source in the Nasdaq market activity article 'MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value'.Clover Health Investments (NASDAQ: CLOV) released new evidence through its Counterpart Health subsidiary showing that primary care physicians using the Counterpart Assistant AI platform were associated with 22% fewer flu-related acute care encounters in COPD patients and 18% fewer in congestive heart failure patients. Patients whose physicians actively engaged with the platform's flu-related clinical insight were 1.89 times more likely to receive flu vaccination than those in the CA cohort whose providers did not engage with the task."The reductions in flu-related hospitalizations and emergency visits among high-risk patients reflect what we've seen within Clover Health's Medicare Advantage population," said Conrad Wai, CEO of Counterpart Health. "Equipping primary care with timely, actionable insights enables earlier intervention, fewer avoidable acute events, and lower total cost of care. It's not plan-specific. It's a scalable model enabling effective value-based care."The whitepaper, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care," underscores Clover Health Investments' strategy of expanding the Counterpart Health platform beyond its own Medicare Advantage membership to serve a broader national provider base. The company continues developing AI-enabled clinical workflows targeting chronic disease management and value-based performance across Medicare populations.Soutce: <a href="https://www.nasdaq.com/press-release/medtechs-edge-how-ai-and-remote-diagnostics-drive-scalable-value-2026-03-27">https://www.nasdaq.com/press-release/medtechs-edge-how-ai-and-remote-diagnostics-drive-scalable-value-2026-03-27</a>Company AnnouncementsClover Health Investments Corp, LivaNova PLC, Microbot Medical Inc, Senseonics Holdings Inc, VentriPoint Diagnostics LtdMedTech's Edge: How AI and Remote Diagnostics Drive Scalable Valuehttps://www.ey.com/en_us/insights/strategy/healthcare-sector-outlook-in-2026https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/https://www.beckersasc.com/asc-transactions-and-valuation-issues/the-biggest-asc-investments-so-far-in-2026/<a href="https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investments">https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investments</a>

Nelson Advisors referenced in the Nasdaq market activity article 'MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value'

Nelson Advisors blog Healthcare.Digital has been referenced as a source in the Financial Times article 'MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value'.Clover Health Investments (NASDAQ: CLOV) released new evidence through its Counterpart Health subsidiary showing that primary care physicians using the Counterpart Assistant AI platform were associated with 22% fewer flu-related acute care encounters in COPD patients and 18% fewer in congestive heart failure patients. Patients whose physicians actively engaged with the platform's flu-related clinical insight were 1.89 times more likely to receive flu vaccination than those in the CA cohort whose providers did not engage with the task."The reductions in flu-related hospitalizations and emergency visits among high-risk patients reflect what we've seen within Clover Health's Medicare Advantage population," said Conrad Wai, CEO of Counterpart Health. "Equipping primary care with timely, actionable insights enables earlier intervention, fewer avoidable acute events, and lower total cost of care. It's not plan-specific. It's a scalable model enabling effective value-based care."The whitepaper, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care," underscores Clover Health Investments' strategy of expanding the Counterpart Health platform beyond its own Medicare Advantage membership to serve a broader national provider base. The company continues developing AI-enabled clinical workflows targeting chronic disease management and value-based performance across Medicare populations.Soutce: <a href="https://markets.ft.com/data/announce/detail?dockey=600-202603271015CANADANWCANADAPR_C6403-1" data-mce-href="https://markets.ft.com/data/announce/detail?dockey=600-202603271015CANADANWCANADAPR_C6403-1">https://markets.ft.com/data/announce/detail?dockey=600-202603271015CANADANWCANADAPR_C6403-1</a>Company Announcements Clover Health Investments Corp, LivaNova PLC, Microbot Medical Inc, Senseonics Holdings Inc, VentriPoint Diagnostics Ltd MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value<a href="https://www.ey.com/en_us/insights/strategy/healthcare-sector-outlook-in-2026" data-mce-href="https://www.ey.com/en_us/insights/strategy/healthcare-sector-outlook-in-2026">https://www.ey.com/en_us/insights/strategy/healthcare-sector-outlook-in-2026</a><a href="https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/" data-mce-href="https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/">https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/</a><a href="https://www.beckersasc.com/asc-transactions-and-valuation-issues/the-biggest-asc-investments-so-far-in-2026/" data-mce-href="https://www.beckersasc.com/asc-transactions-and-valuation-issues/the-biggest-asc-investments-so-far-in-2026/">https://www.beckersasc.com/asc-transactions-and-valuation-issues/the-biggest-asc-investments-so-far-in-2026/</a><a href="https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investments" data-mce-href="https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investments">https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investments</a>

Nelson Advisors referenced in Financial Times article 'MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value'

Healthcare Business International interviewed Nelson Advisors partner Lloyd Price discussing Healthbridge's acquisition of AI scribe Nora.“The acquisition highlights a broader shift in the industry, as companies are leaning more toward acquisitions instead of building everything in-house,” Lloyd Price, partner at M&amp;A advisory firm Nelson Advisors told HBI.From an investment perspective, the focus is on clinical AI tools that can “demonstrate productivity and efficiency gains whilst growing their user base month after month.”“Healthtech investors are adapting fast too. AI native startups now command higher revenue multiples (typically 9×–14×) thanks to their proprietary datasets and scalable automation potential. Exit timelines are tightening as well, with many “incubation‑to‑exit” deals wrapping up in under three years,” said Price.“Altogether, valuations are breaking away from speculative tech trends and increasingly rewarding platforms that serve as core clinical operating systems rather than optional add‑ons,” he further added. Investors are increasingly focusing on metrics such as annual recurring revenue per clinician and outcome-based pricing that reflect “tangible clinical improvements” as value creation levers.The acquisition also highlights the rapid growth in South Africa’s healthtech market. The digital health and AI scribe market is quickly “moving from a ‘nice to have’ to an essential tool across both private and public healthcare.”Source: <a href="https://www.healthcarebusinessinternational.com/healthbridge-buys-ai-scribe-nora/">https://www.healthcarebusinessinternational.com/healthbridge-buys-ai-scribe-nora/</a>Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

Healthcare Business International interviewed Nelson Advisors partner Lloyd Price discussing Healthbridge's acquisition of AI scribe Nora

Major HealthTech themes this week: fresh EU funding calls (Digital Europe, EIT Health), tightening AI-in-healthcare guardrails under the AI Act, and continued shift toward clinically validated, sovereign‑cloud digital infrastructure.Policy and regulation The Commission has updated guidance on how the AI Act dovetails with MDR/IVDR, raising expectations on data quality, risk management, and human oversight for high‑risk AI medical software. The EU Health Technology Assessment (HTA) framework is now fully live, with joint clinical assessments ramping and effectively lifting the evidence bar for pan‑EU market access, particularly for digital and AI‑enabled devices. Recent commentary stresses that the AI Act gives patients an explicit legal basis to demand understandable explanations of AI‑shaped medical decisions, which will force explainability and product‑design changes in clinical AI tools. EU and pan-European funding levers A new round of Digital Europe calls opens 21 April 2026, including topics on AI‑based image screening, digital solutions for regulatory compliance through data, and advanced skills for AI uptake in health, with a 1 October 2026 deadline. EIT Health’s 2026 Innovation Validation Call offers up to €850k per project (50% co‑funding) for late‑stage digital health projects ready for clinical validation and launch; micro and small enterprises must take €400k–€500k of the grant at the commercialising entity. The EIC has awarded €118m to 30 deep‑tech projects, with a sizeable share into healthy‑ageing biotech and modular multi‑robot surgical assistance platforms, reinforcing the robotics and longevity stack in Europe. Market, product and infra moves BD has launched its Pyxis Pro medication dispensing and Incada Connected Care platforms in Europe, hosted on AWS European Sovereign Cloud to square scale with EU data‑sovereignty and localisation requirements. CMR Surgical’s Versius Plus robotic platform has now passed 40,000 procedures and is building out a richer digital analytics suite in Europe alongside a 2026 US commercial push, signalling continued convergence of robotics and data services. Johnson &amp; Johnson has released one‑year data for ICOTYDE, paired with new digital adherence monitoring tools tailored to European payers, highlighting the bundling of therapeutics with digital companions. Capital flows and ecosystem signals Q1 2026 global digital health funding reached about $7.1bn across 216 deals, with Europe second by region at roughly $1.16bn, driven notably by France (~$323m) and Switzerland (~$302m), underscoring a resilient European capital base despite modest YoY softness. Analysts continue to characterise the current phase as a “Great Rationalization” in European HealthTech, with capital and corporate attention shifting from experimental AI to clinically validated, scalable solutions and robust cloud/data infrastructure. Near-term conferences and platforms to watch DMEA (Berlin, 21–23 April 2026) remains the flagship digital health fair in Europe with around 900 exhibitors, 20,500 visitors and hundreds of speakers, and will be a key venue for AI‑in‑EHR and hospital IT announcements. The European Digital HealthTech Conference 2026 in Luxembourg is focusing on real-world adoption of digital medical devices and trusted solutions, drawing startups, corporates, and policymakers around implementation challenges.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;&nbsp;Key MedTech themes this week: MDR/IVDR “smarter certification” reform, the EUDAMED go‑live countdown, and UK moves to lock in long‑term CE reliance, all against a backdrop of EU funding and robotics/healthy‑ageing pushes.Regulatory moves and compliance pressure The Commission’s targeted MDR/IVDR simplification advances, including removal of the rigid five‑year certificate validity cap in favour of continuous, risk‑based surveillance to ease notified‑body bottlenecks. Four key EUDAMED modules (actor, UDI/device, certificates, market surveillance) become mandatory on 28 May 2026; industry bodies are urging manufacturers to complete data validation now given litigation and transparency exposure. The MHRA’s consultation (closing 10 April 2026) proposes indefinite recognition of CE‑marked devices in Great Britain under its International Reliance Framework, materially simplifying dual‑EU/UK strategies if adopted. Strategic industry stance MedTech Europe publicly backed the MDR/IVDR simplification package, framing it as a necessary correction to high compliance costs, unpredictable timelines, and risk‑classification issues that have constrained innovation and availability. Legal and consultancy commentary this week emphasises that the reform aims to restore competitiveness and innovation while maintaining safety, suggesting a more pragmatic risk‑benefit balance for SMEs and niche device players. Funding, innovation and robotics The EIC just awarded €118m Pathfinder funding to 30 breakthrough projects, with a notable share going to biotechnology for healthy ageing and modular multi‑robot surgical assistance platforms, reinforcing the surgical robotics pipeline in Europe. New Horizon Europe HORIZON‑HLTH‑2026 calls are open, with MedTech‑relevant topics including regulatory science for patient‑centred tech, NAMs to replace animal testing in device validation, and scaling cardiovascular innovation (including AI wearables). EU4Health signed three new pre‑commercial procurement framework contracts (ceiling €225m over 98 months) to advance pandemic preparedness and vaccine innovation, signalling sustained device‑adjacent public investment in prevention and emergency tooling. Market, product and infra signals BD’s launch of Pyxis Pro medication dispensing and Incada Connected Care across Europe, built on cloud infrastructure, highlights hospital buyers’ focus on integrated medication management and connected‑care platforms. CMR Surgical’s Versius Plus robotic system has now passed 40,000 procedures and is intensifying its digital analytics offering in Europe while preparing for a 2026 U.S. commercial push, underlining the data‑services layer around capital equipment. Near‑term events and forums MedTech Europe and leading firms are positioning April–June conferences (e.g., MedTech Summit Berlin in June) as key venues to unpack MDR/IVDR reform, EUDAMED implementation, and AI‑related compliance expectations.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 10th April 2026

According to a recent LinkedIn post from AMT Medical, the company has been included by Nelson Advisors among 20 future Dutch healthtech and medtech leaders. The post highlights AMT Medical’s focus on advancing coronary surgery through its Elana® Anastomotic System, which is described as enabling faster, reproducible and minimally invasive coronary bypass procedures by targeting the distal anastomosis bottleneck in CABG.The LinkedIn post suggests that this external recognition coincides with several strategic priorities, including progress toward CE and FDA marking, strengthening clinical validation and pursuing partnerships with global industry players. For investors, these aims, if achieved, could support future commercialization, enhance regulatory visibility and position AMT Medical as a differentiated player in off-pump, MIDCAB and robotic cardiac surgery markets within the broader medtech ecosystem.Source: <a href="https://www.tipranks.com/news/private-companies/amt-medical-highlighted-as-emerging-dutch-medtech-leader-with-focus-on-coronary-surgery-innovation" data-mce-href="https://www.tipranks.com/news/private-companies/amt-medical-highlighted-as-emerging-dutch-medtech-leader-with-focus-on-coronary-surgery-innovation">https://www.tipranks.com/news/private-companies/amt-medical-highlighted-as-emerging-dutch-medtech-leader-with-focus-on-coronary-surgery-innovation</a>TipRanks is a financial research platform that uses AI and big data to rank financial experts and turn their recommendations into actionable stock insights for investors.What TipRanks doesAggregates analyst ratings, financial blogger opinions, hedge fund activity, insider trades, and news into a unified view for each stock.Ranks over tens of thousands of analysts and financial professionals by historical performance (success rate, average return, statistical significance). Provides consensus ratings (buy/hold/sell), price targets, and track records for each expert and each stock. Assigns each stock a 1–10 “Smart Score” based on eight factors, including analyst sentiment, insider activity, hedge fund activity, and technicals. Key features Analyst &amp; blogger tracking: See which analysts have the best long‑term record and filter stock ideas to “top” experts only. Smart Score stock ratings: Quick 1–10 rating per stock, with historically strong performance for high‑score names. Insider &amp; hedge fund tools: View which stocks are seeing significant insider buying/selling and hedge fund accumulation or trimming. Portfolio tools: Build and track portfolios, see aggregated analyst sentiment and risk factors for your holdings. Markets and access (incl. UK) Originally focused on US markets (NYSE/Nasdaq), TipRanks has expanded to cover Canada and the UK, tracking hundreds of UK-focused analysts. UK investors can access TipRanks directly via its website or through brokers that have integrated it (for example, IG and Interactive Brokers offer TipRanks tools in-platform).

Nelson Advisors

Blog

Nelson Advisors served as co-advisors to Zetta Genomics o...

Nelson Advisors referenced in the Nasdaq market activity ...

Nelson Advisors referenced in Financial Times article 'Me...

Healthcare Business International interviewed Nelson Advi...

This Week in European MedTech and HealthTech: 10th April ...

Nelson Advisors featured on TipRanks.com discussing Dutch...